Deactivation rate of camptothecin determined by factor analysis of steady-state fluorescence and absorption spectra

• Autorzy: Ziomkowska B. , Kruszewski S. , Siuda R. , Cyrankiewicz M.
• Języki publikacji: EN

Abstrakty

EN

Camptothecin is a fluorescent compound exhibiting strong anticancer properties. A serious limitation to clinical application of this compound is its hydrolysis, when biologically active lactone form converts into inactive carboxylate. There are some differences in the shapes of both fluorescence and absorption spectra of the lactone and carboxylate forms of camptothecin. Therefore, during hydrolysis resultant fluorescence and absorption spectra evolve. Factor analysis of fluorescence/absorption spectra recorded during the hydrolysis process of camptothecin enables one to determine the temporary concentration of the lactone and carboxylate forms and obtain the deactivation rate of this compound.

Słowa kluczowe

EN

camptothecin; fluorescence; absorption; factor analysis

• Wydawca: Oficyna Wydawnicza Politechniki Wrocławskiej
• Czasopismo: Optica Applicata
• Rocznik: 2006
• Tom: Vol. 36, nr 1
• Strony: 137--146
• Opis fizyczny: Bibliogr. 17 poz.,

Twórcy

autor

Ziomkowska B.

autor

Kruszewski S.

autor

Siuda R.

autor

Cyrankiewicz M.

• Collegium Medicum of N. Copernicus University, ul. Jagiellońska 13, 85-067 Bydgoszcz Poland

Bibliografia

• [1] WALL M.E., WANI M.C., COOK C.E., PALMER K.H., MCPHAIL A.T., SIM G.A., Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata, Journal of the American Chemical Society 88(16), 1966, pp. 3888–90.
• [2] LIU L.F., DESAI S.D., LI T-K., MAO Y., SUN M., SIM S-P., Mechanism of action of camptothecin, Annals of the New York Academy of Sciences 922, 2000, pp. 1–10.
• [3] LAKOWICZ J.R., Principles of Fluorescence Spectroscopy, Kluwer Academic/Plenum Publisher, New York 1999.
• [4] KRUSZEWSKI S., BURKE T.G., Camptothecins affinity to HSA and membranes determined by fluorescence anisotropy measurements, Optica Applicata 32(4), 2002, pp. 721–30.
• [5] MI Z., BURKE T.G., Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study, Biochemistry 33(42), 1994, pp. 12540–5.
• [6] MI Z., BURKE T.G., Differential interactions of camptothecin lactone and carboxylate forms with human blood components, Biochemistry 33(34), 1994, pp. 10325–36.
• [7] CHOURPA I., MILLOT J.-M., SOCKALINGUM G.D., RIOU J.-F., MANFAIT M., Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy, Biochimica et Biophysica Acta 1379(3), 1998, pp. 353–66.
• [8] JOLLIFEE I.T., Principal Component Analysis, Springer Verlag, New York, Berlin, Heilderberg, Tokyo 1986.
• [9] MALINOWSKI E.R., Factor Analysis in Chemistry, Second Ed., Wiley, New York, Chichester 1991.
• [10] BIAŁEK H., System for computer recording and analysis of fluorescence spectra using monochromator SPM-2, Diploma Thesis, Institute of Mathematics and Physics, University of Technology and Agriculture, Bydgoszcz, Poland 2003 (in Polish).
• [11] KRUSZEWSKI S., SIUDA R., ZIOMKOWSKA B., CYRANKIEWICZ M., Application of principal component and factor analysis of fluorescence spectra in camptothecin studies, Optica Applicata 33(2-3), 2003, pp. 369–80.
• [12] KRUSZEWSKI S., SIUDA R., ZIOMKOWSKA B., CYRANKIEWICZ M., PCA and FA analysis of steady-state fluorescence spectra of camptothecin, Proceedings of the SPIE 5064, 2003, pp. 84–90.
• [13] BURKE T.G., MI Z., The structural basis of camptothecin interactions with human serum albumin: impact on drug stability, Journal of Medicinal Chemistry 37(1), 1994, pp. 40–6.
• [14] BURKE T.G., STAUBUS A.E., MISHRA A.K., MALAK H., Liposomal stabilization of camptothecin’s lactone ring, Journal of the American Chemical Society 114(21), 1992, pp. 8318–9.
• [15] BURKE T.G., BOM D., Campthotecin design and delivery approaches for elevating anti- -topoisomerase I activities in vivo, Annals of the New York Academy of Sciences 922, 2000, pp. 36–45.
• [16] LAVERGNE O., DEMARQUAY D., KASPRZYK P.G., BIGG D.C.H., Homocamptothecins: E-ring modified CPT analogues, Annals of the New York Academy of Sciences 922, 2000, pp. 100–11.
• [17] CURRAN D.P., JOSIEN H., BOM D., GABARDA A.E., DU W., The cascade radical annulation approach to new analogues of camptothecins: combinatorial synthesis of silatecans and homosilatecans, Annals of the New York Academy of Sciences 922, 2000, pp. 112–21. Received July 7, 2005 in revised form September 22, 2005